Evidence map›Paper›PMID 24150225›Full record

ArticleTranslational psychiatry2013

Transcriptional regulation of the MET receptor tyrosine kinase gene by MeCP2 and sex-specific expression in autism and Rett syndrome.

J T Plummer, O V Evgrafov, M Y Bergman, M Friez, C A Haiman, P Levitt, K A Aldinger

Open access · goldAbstract read
In one paragraph

Article in Translational psychiatry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 39 citations in OpenAlex.

  1. Developmental and molecular contributions to contextual fear memory emergence in mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. HGF and MET: From Brain Development to Neurological Disorders.Frontiers in cell and developmental biology · 2021
    Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

J T PlummerZilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
O V Evgrafov
M Y Bergman
M Friez
C A Haiman
P Levitt
K A Aldinger
University of Southern California · USGreenwood Genetic Center · USSeattle Children's Hospital · USVanderbilt University · US

Funding

Function &Structure Adaptation in Forebrain DevelopmentR01MH067842 · NIMH · VANDERBILT UNIVERSITY · PI LEVITT, PAT · 2002 to 2023
$10.8M
Los Angeles Basin Clinical and Translational Science InstituteKL2RR031991 · NCRR · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BUCHANAN, THOMAS A · 2010 to 2011
$1.6M
Function and Structure Adaptations in Forebrain DevelopmentR56MH067842 · NIMH · CHILDREN'S HOSPITAL OF LOS ANGELES · PI LEVITT, PAT · 2014 to 2014
$662k
NIMH NIH HHS MH067842NIMH NIH HHS R01 MH067842NIMH NIH HHS R56 MH067842
6 · The paper itself

Abstract

Single nucleotide variants (SNV) in the gene encoding the MET receptor tyrosine kinase have been associated with an increased risk for autism spectrum disorders (ASD). The MET promoter SNV rs1858830 C 'low activity' allele is enriched in ASD, associated with reduced protein expression, and impacts functional and structural circuit connectivity in humans. To gain insight into the transcriptional regulation of MET on ASD-risk etiology, we examined an interaction between the methyl CpG-binding protein 2 (MeCP2) and the MET 5' promoter region. Mutations in MeCP2 cause Rett syndrome (RTT), a predominantly female neurodevelopmental disorder sharing some ASD clinical symptoms. MeCP2 binds to a region of the MET promoter containing the ASD-risk SNV, and displays rs1858830 genotype-specific binding in human neural progenitor cells derived from the olfactory neuroepithelium. MeCP2 binding enhances MET expression in the presence of the rs1858830 C allele, but MET transcription is attenuated by RTT-specific mutations in MeCP2. In the postmortem temporal cortex, a region normally enriched in MET, gene expression is reduced dramatically in females with RTT, although not due to enrichment of the rs1858830 C 'low activity' allele. We newly identified a sex-based reduction in MET expression, with male ASD cases, but not female ASD cases compared with sex-matched controls. The experimental data reveal a prominent allele-specific regulation of MET transcription by MeCP2. The mechanisms underlying the pronounced reduction of MET in ASD and RTT temporal cortex are distinct and likely related to factors unique to each disorder, including a noted sex bias.

Indexed as

Autistic DisorderFemaleGene Expression RegulationGenotypeHumansMaleMethyl-CpG-Binding Protein 2MutationNeuroepithelial CellsPhenotypePolymorphism, Single NucleotidePromoter Regions, GeneticProto-Oncogene Proteins c-metReal-Time Polymerase Chain ReactionRett SyndromeSex FactorsMECP2 protein, humanMethyl-CpG-Binding Protein 2MET protein, humanProto-Oncogene Proteins c-met

Identifiers

PMID24150225
PMCPMC3818007
OpenAlexW2046925087

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.